On the recordNovember 16, 2017
I ask unanimous consent that the text of the bill be printed in the Record. There being no objection, the text of the bill was ordered to be printed in the Record, as follows: S. 2157 Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``Drug-Price Transparency in Communications Act''. SEC. 2. FINDINGS. Congress finds as follows: (1) Direct-to-consumer advertising of prescription pharmaceuticals is legal in only 2 developed countries, the United States and New Zealand. (2) Direct-to-consumer advertising of prescription pharmaceuticals is designed to cause patients to pressure physicians to prescribe certain medications. (3) In 2015, pharmaceutical companies spent more than $100,000,000 on advertising with respect to each of 16 brand- name drugs, primarily new and expensive drugs. (4) Prescription rates of medications advertised directly to consumers have increased by 34.2 percent compared to a 5.1 percent increase in other pharmaceuticals. (5) Prescription pharmaceuticals cost more in the United States than they do in any other country. (6) The American Medical Association has passed resolutions calling for the ban of direct-to-consumer advertising of prescription pharmaceuticals, and to require price transparency in any direct-to-consumer advertising.…





